MedTrace Logo

Honey and Nigella Sativa in COVID-19 Prophylaxis

NCT04767087 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2021-07-02

No results posted yet for this study

Summary

Honey and Nigella sativa has established antiviral, antibacterial, anti-inflammatory, and immunomodulatory roles. So it is planned to test for its prophylaxis

Conditions

  • Covid19

Interventions

DRUG

Honey

0.5 gm/Kg/day honey

DRUG

Nigella sativa seed

40 mg/Kg/day

OTHER

Placebo

empty capsule with sugar water

Sponsors & Collaborators

  • Sohaib Ashraf

    lead OTHER

Principal Investigators

  • Sohaib Ashraf, MBBS · Massachusetts General Hospital

  • Muhammad Ashraf, PhD · University of Veterinary and Animal Sciences

  • Ahmad Imran, MBBS · Shaikh Zayed Post-Graduate Medical Institute

  • Moneeb Ashraf, MBBS · King Edward Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2022-02-15
Completion
2022-04-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04767087 on ClinicalTrials.gov